Femasys (NASDAQ:FEMY) Issues Quarterly Earnings Results

Femasys (NASDAQ:FEMY) issued its quarterly earnings results on Tuesday. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.04), Zacks reports. Femasys had a negative return on equity of 120.13% and a negative net margin of 1,435.77%. The business had revenue of $0.55 million during the quarter, compared to the consensus estimate of $0.40 million.

Femasys Trading Up 0.5 %

NASDAQ:FEMY traded up $0.01 during mid-day trading on Wednesday, hitting $1.04. The company had a trading volume of 274,081 shares, compared to its average volume of 333,511. The company has a current ratio of 6.47, a quick ratio of 5.93 and a debt-to-equity ratio of 0.43. Femasys has a fifty-two week low of $0.73 and a fifty-two week high of $2.40. The business’s fifty day moving average is $1.16 and its two-hundred day moving average is $1.15.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on FEMY. Chardan Capital lowered their target price on shares of Femasys from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Femasys in a research report on Tuesday.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.